3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
26
Burkitt Lymphoma
12
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
7
Leukemia
4
Recurrence
2
Leukemia, Biphenotypic, Acute
2
Hematologic Neoplasms
2
Philadelphia Chromosome
1
Lymphoma
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Blast Crisis
1
Interventions
Imatinib Mesylate
14
Dasatinib
5
nilotinib
4
bosutinib
4
Cyclophosphamide
4
fludarabine
3
Vincristine
3
Methotrexate
3
Dexamethasone
3
Cytarabine
3
peginterferon alfa-2a
2
fludarabine phosphate
2
asciminib
2
Prednisone
2
Daunorubicin
2
Azacitidine
2
Acetaminophen
2
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide
2
venetoclax
1
thymoglobulin
1
ponatinib
1
olverembatinib
1
flumatinib
1
blinatumomab
1
Whole-Body Irradiation
1
Tyrosine Kinase Inhibitors
1
Tacrolimus
1
Rituximab
1
Prednisolone
1
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Philadelphia Chromosome
×
Inotuzumab Ozogamicin
×
Other hematologic neoplasm
×
Clear all
NCT03249870
2023-09-06
EWALL-INO
Versailles Hospital
Phase 2
Unknown
130 enrolled